Expression Levels of miR-146b and Anti-Cardiac Troponin I in Serum of Children with Viral Myocarditis and Their Clinical Sig-nificance
Background: To investigate the expression levels of microRNA-146b (miR-146b) and cardiac troponin I (anti-cTnI) in serum of children with viral myocarditis and their clinical significance.
Methods: Forty-eight children with viral myocarditis (patient group) and 40 healthy physical examinees (healthy group), who were diagnosed in Jinan City People’s Hospital Affiliated to Shandong First Medical University, China from Feb 2018 to May 2019, were enrolled as study subjects. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the level of miR-146b in serum of children. ELISA was used to detect the expression of anti-cTnI in serum of children. Pearson was used to analyze the correlation between the level of miR-146b and the level of anti-cTnI, and the factors affecting the prognosis.
Results: The levels of miR-146b and anti-cTnI in serum of children in patient group were statistically significantly higher than those of healthy group (P<0.01). The AUC of miR-146b was 0.741, (95% CI: 0.638-0.843), the specificity was 62.50%, the sensitivity was 82.50%, and the AUC of anti-cTnI was 0.720 (95% CI: 0.608-0.832), the specificity was 64.58% and the sensitivity was 92.50%. The level of miR-146b was positively correlated with the level of anti-cTnI (r=0.601, P<0.05). CK-MB, LVEF, miR-146b and anti-cTnI expression were independent risk factors affecting the prognosis.
Conclusion: The levels of miR-146b and anti-cTnI increased in serum of patients with viral myocarditis. They were related to the degree of myocardial injury, which indicated that miR-146b and anti-cTnI might be involved in the pathological process of viral myocarditis.
2. Ellis CR, Di Salvo T (2007). Myocarditis: basic and clinical aspects. Cardiol Rev, 15(4): 170-177.
3. Burke JD, Sonenberg N, Platanias LC, et al (2011). Antiviral effects of interferon-beta are enhanced in the absence of the trans-lational suppressor 4E-BP1 in myocardi-tis induced by Coxsackievirus B3. Antivir Ther, 16(4): 577-584.
4. Pollack A, Kontorovich AR, Fuster V, et al (2015). Viral myocarditis-diagnosis, treatment options, and current contro-versies. Nat Rev Cardiol, 12(11): 670-680.
5. Farazi T A, Spitzer J I, Morozov P, et al (2011). miRNAs in human cancer. J Pathol, 223(2): 102-115.
6. Slaby O, Krekac D, Hrstka R, et al (2008). Involvement of microRNAs in cancer biology and possibilities of their applica-tion to diagnostic and predictive oncolo-gy. Cas Lek Cesk, 147(1): 25-31.
7. Ke TW, Wei PL, Yeh KT, et al (2015). MiR-92a Promotes Cell Metastasis of Colorec-tal Cancer Through PTEN-Mediated PI3K/AKT Pathway. Ann Surg Oncol, 22(8): 2649-2655.
8. McManus DD, Freedman JE (2015). Mi-croRNAs in platelet function and cardio-vascular disease. Nat Rev Cardiol, 12(12): 711-717.
9. Nagatomo Y, Tang WH (2014). Autoanti-bodies and cardiovascular dysfunction: cause or consequence? Curr Heart Fail Rep, 11 (4): 500-508.
10. Cheng HS, Sivachandran N, Lau A, et al (2013). MicroRNA‐146 represses endo-thelial activation by inhibiting pro‐inflammatory pathways. EMBO Mol Med, 5(7): 1017-1034.
11. Shi C, Zhu L, Chen X, et al (2014). IL-6 and TNF-α induced obesity-related inflamma-tory response through transcriptional regulation of miR-146b. J Interferon Cyto-kine Res, 34(5): 342-348.
12. Liu YL, Wu W, Xue Y, et al (2013). Mi-croRNA-21 and-146b are involved in the pathogenesis of murine viral myocarditis by regulating TH-17 differentiation. Arch Virol, 158(9): 1953-1963.
13. Chen ZG, Liu H, Zhang JB, et al (2015). Upregulated microRNA-214 enhances cardiac injury by targeting ITCH during coxsackievirus infection. Mol Med Rep, 12(1): 1258-1264.
14. Tsikitis M, Galata Z, Mavroidis M, et al (2018). Intermediate filaments in cardio-myopathy. Biophys Rev, 10(4): 1007-1031.
15. Okazaki T, Honjo T (2005). Pathogenic roles of cardiac autoantibodies in dilated cardi-omyopathy. Trends Mol Med, 11(7): 322-326.
16. Haider KH, Stimson WH (1995). Production and characterisation of anti-cardiac tro-ponin-I monoclonal antibodies. Dis Markers, 12(3): 187-197.
17. Parrillo JE (2001). Inflammatory cardiomyo-pathy (myocarditis) which patients should be treated with anti-inflammatory thera-py? Circulation, 104 (1): 4-6.
18. Kalra A, Kneeland R, Samara MA, et al (2014). The Changing Role for Endomy-ocardial Biopsy in the Diagnosis of Gi-ant-Cell Myocarditis. Cardiol Ther, 3(1-2): 53-59.
19. Cooper LT, Baughman KL, Feldman AM, et al (2007). The role of endomyocardial biopsy in the management of cardiovas-cular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circula-tion, 116(19): 2216-2233.
20. Corsten MF, Schroen B, Heymans S (2012). Inflammation in viral myocarditis: friend or foe? Trends Mol Med, 18 (7): 426-437.
21. Matshela MR (2019). The role of echocardi-ography in acute viral myocarditis. Cardio-vasc J Afr, 30 (4): 239-44.
22. Remels AHV, Derks WJA, Cillero-Pastor B, et al (2018). Inflammation-induced meta-bolic remodelling of the heart in acute vi-ral myocarditis. Biochim Biophys Acta Mol Basis Dis, 1864(8): 2579-2589.
23. Wilczynska A, Bushell M (2015). The com-plexity of miRNA-mediated repression. Cell Death Differ, 22 (1): 22-33.
24. Qian B, Katsaros D, Lu L, et al (2008). High miR-21 expression in breast cancer asso-ciated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat, 117(1): 131-140.
25. Zhang Z, Li H, Zhao Z, et al (2019). miR-146b level and variants is associated with endometriosis related macrophages phe-notype and plays a pivotal role in the en-dometriotic pain symptom. Taiwan J Ob-stet Gynecol, 58(3): 401-408.
26. Isserlin R, Merico D, Wang D, et al (2014). Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy. Mol Biosyst, 11(1): 239-251.
27. McNally EM, Mestroni L (2017). Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res, 121 (7): 731-748.
28. Goldberg L, Tirosh-Wagner T, Vardi A, et al (2018). Circulating MicroRNAs: a Po-tential Biomarker for Cardiac Damage, Inflammatory Response, and Left Ven-tricular Function Recovery in Pediatric Vi-ral Myocarditis. J Cardiovasc Transl Res, 11(4): 319-328.
29. Mitsumura T, Ito Y, Chiba T, et al (2018). Ablation of miR-146b in mice causes hemato-poietic malig-nancy. Blood Adv, 2(23): 3483-3491.
30. Ilva T, Lund J, Porela P, et al (2009). Early markers of myocardial injury: cTnI is enough. Clin Chim Acta, 400(1-2): 82-85.
31. Tang G, Wu Y, Zhao W, et al (2012). Multiple im-munoassay systems are negatively interfered by circulating cardiac troponin I autoantibodies. Clin Exp Med, 12(1): 47-53.
32. Fan Y, Chen Y, Wan Z, et al (2017). The prognostic value of autoantibodies against β1-adrenoceptor and cardiac troponin-I for clinical outcomes in STEMI. J Cardiovasc Med (Hagerstown), 18(1): 34-41.
|Issue||Vol 50 No 3 (2021)|
|microRNA-146b Cardiac troponin I Viral myocarditis Clinical significance|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|